Vertex tiptoes further into Duchenne research with Tevard deal

Vertex Pharmaceuticals is committing further to Duchenne muscular dystrophy research, announcing on Tuesday a deal with biotechnology startup Tevard Biosciences to develop RNA-based therapies for the progressive genetic condition.